Muscarinic cholinergic receptors in mammalian brain: differences between bindings of acetylcholine and atropine. 1978

S Uchida, and K Takeyasu, and S Ichida, and H Yoshida

Studies were made on the bindings of [3H]-acetylcholine and [3H]-atropine to synaptic plasma membranes from rat brain. Synaptic plasma membranes have reversible, high affinity binding sites for both ligands, the KD values for ACh and atropine being about 20 nM and 1 nM, respectively. The maximal binding capacities for ACh and atropine, respectively, are 0.8-1.2 pmoles and about 1.5 pmoles/mg protein of synaptic membranes. The specific binding of ACh is almost completely inhibited by oxotremorine and atropine. 5,5'-Dithiobis (2-nitrobenzoic acid) (DTNB) increased the ACh-binding to about 1.5 pmole/mg protein. It also increased the inhibition of atropine-binding by ACh about 10-fold. Marked discrepancies were found in the inhibitions of atropine- and ACh-bindings by muscarinic agonists, but not in the inhibitions by antagonists. These findings support the hypothesis that muscarinic receptors have different sites for agonists and antagonists. The possibility that one receptor can be simultaneously occupied by both an agonist and an antagonist is also discussed.

UI MeSH Term Description Entries
D010277 Parasympathomimetics Drugs that mimic the effects of parasympathetic nervous system activity. Included here are drugs that directly stimulate muscarinic receptors and drugs that potentiate cholinergic activity, usually by slowing the breakdown of acetylcholine (CHOLINESTERASE INHIBITORS). Drugs that stimulate both sympathetic and parasympathetic postganglionic neurons (GANGLIONIC STIMULANTS) are not included here. Parasympathomimetic Agents,Parasympathomimetic Drugs,Parasympathomimetic Effect,Parasympathomimetic Effects,Agents, Parasympathomimetic,Drugs, Parasympathomimetic,Effect, Parasympathomimetic,Effects, Parasympathomimetic
D011950 Receptors, Cholinergic Cell surface proteins that bind acetylcholine with high affinity and trigger intracellular changes influencing the behavior of cells. Cholinergic receptors are divided into two major classes, muscarinic and nicotinic, based originally on their affinity for nicotine and muscarine. Each group is further subdivided based on pharmacology, location, mode of action, and/or molecular biology. ACh Receptor,Acetylcholine Receptor,Acetylcholine Receptors,Cholinergic Receptor,Cholinergic Receptors,Cholinoceptive Sites,Cholinoceptor,Cholinoceptors,Receptors, Acetylcholine,ACh Receptors,Receptors, ACh,Receptor, ACh,Receptor, Acetylcholine,Receptor, Cholinergic,Sites, Cholinoceptive
D011976 Receptors, Muscarinic One of the two major classes of cholinergic receptors. Muscarinic receptors were originally defined by their preference for MUSCARINE over NICOTINE. There are several subtypes (usually M1, M2, M3....) that are characterized by their cellular actions, pharmacology, and molecular biology. Muscarinic Acetylcholine Receptors,Muscarinic Receptors,Muscarinic Acetylcholine Receptor,Muscarinic Receptor,Acetylcholine Receptor, Muscarinic,Acetylcholine Receptors, Muscarinic,Receptor, Muscarinic,Receptor, Muscarinic Acetylcholine,Receptors, Muscarinic Acetylcholine
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D003864 Depression, Chemical The decrease in a measurable parameter of a PHYSIOLOGICAL PROCESS, including cellular, microbial, and plant; immunological, cardiovascular, respiratory, reproductive, urinary, digestive, neural, musculoskeletal, ocular, and skin physiological processes; or METABOLIC PROCESS, including enzymatic and other pharmacological processes, by a drug or other chemical. Chemical Depression,Chemical Depressions,Depressions, Chemical
D000109 Acetylcholine A neurotransmitter found at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in the central nervous system. 2-(Acetyloxy)-N,N,N-trimethylethanaminium,Acetilcolina Cusi,Acetylcholine Bromide,Acetylcholine Chloride,Acetylcholine Fluoride,Acetylcholine Hydroxide,Acetylcholine Iodide,Acetylcholine L-Tartrate,Acetylcholine Perchlorate,Acetylcholine Picrate,Acetylcholine Picrate (1:1),Acetylcholine Sulfate (1:1),Bromoacetylcholine,Chloroacetylcholine,Miochol,Acetylcholine L Tartrate,Bromide, Acetylcholine,Cusi, Acetilcolina,Fluoride, Acetylcholine,Hydroxide, Acetylcholine,Iodide, Acetylcholine,L-Tartrate, Acetylcholine,Perchlorate, Acetylcholine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001285 Atropine An alkaloid, originally from Atropa belladonna, but found in other plants, mainly SOLANACEAE. Hyoscyamine is the 3(S)-endo isomer of atropine. AtroPen,Atropin Augenöl,Atropine Sulfate,Atropine Sulfate Anhydrous,Atropinol,Anhydrous, Atropine Sulfate,Augenöl, Atropin,Sulfate Anhydrous, Atropine,Sulfate, Atropine
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013438 Sulfhydryl Compounds Compounds containing the -SH radical. Mercaptan,Mercapto Compounds,Sulfhydryl Compound,Thiol,Thiols,Mercaptans,Compound, Sulfhydryl,Compounds, Mercapto,Compounds, Sulfhydryl

Related Publications

S Uchida, and K Takeyasu, and S Ichida, and H Yoshida
June 1978, Brain research,
S Uchida, and K Takeyasu, and S Ichida, and H Yoshida
July 1978, Life sciences,
S Uchida, and K Takeyasu, and S Ichida, and H Yoshida
February 1986, Life sciences,
S Uchida, and K Takeyasu, and S Ichida, and H Yoshida
February 1981, Analytical biochemistry,
S Uchida, and K Takeyasu, and S Ichida, and H Yoshida
June 2004, British journal of pharmacology,
S Uchida, and K Takeyasu, and S Ichida, and H Yoshida
June 1983, Biochemical pharmacology,
S Uchida, and K Takeyasu, and S Ichida, and H Yoshida
February 1992, Journal of neurology,
S Uchida, and K Takeyasu, and S Ichida, and H Yoshida
June 1985, The Journal of neuroscience : the official journal of the Society for Neuroscience,
S Uchida, and K Takeyasu, and S Ichida, and H Yoshida
January 2011, PloS one,
S Uchida, and K Takeyasu, and S Ichida, and H Yoshida
June 1983, Acta medica Okayama,
Copied contents to your clipboard!